Fcpm Iii Services B.V. Takes Position in Maplight Therapeutics, Inc. $MPLT

Posted by Brian Himes on Jun 17th, 2026

Fcpm Iii Services B.V. bought a new stake in Maplight Therapeutics, Inc. (NASDAQ:MPLT – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 3,226,400 shares of the company’s stock, valued at approximately $56,672,000. Maplight Therapeutics accounts for about 7.5% of Fcpm Iii Services B.V.’s holdings, making the stock its 5th largest position. Fcpm Iii Services B.V. owned approximately 0.07% of Maplight Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $70,000. New York State Common Retirement Fund purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $93,000. MetLife Investment Management LLC purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $172,000. Finally, Walleye Capital LLC purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $205,000.

Analysts Set New Price Targets

Several research firms have recently weighed in on MPLT. Craig Hallum began coverage on Maplight Therapeutics in a report on Thursday, May 21st. They issued a “buy” rating and a $43.00 target price for the company. Canaccord Genuity Group began coverage on Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price for the company. Wall Street Zen downgraded Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. TD Cowen began coverage on Maplight Therapeutics in a research note on Tuesday, April 7th. They set a “buy” rating for the company. Finally, UBS Group began coverage on Maplight Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $48.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Maplight Therapeutics has a consensus rating of “Buy” and an average price target of $37.78.

Read Our Latest Report on Maplight Therapeutics

Insider Buying and Selling at Maplight Therapeutics

In other news, insider Anatol Kreitzer sold 45,422 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $29.66, for a total transaction of $1,347,216.52. Following the completion of the transaction, the insider directly owned 211,190 shares of the company’s stock, valued at approximately $6,263,895.40. This represents a 17.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $28.76, for a total value of $713,564.36. Following the transaction, the insider directly owned 243,450 shares of the company’s stock, valued at approximately $7,001,622. This trade represents a 9.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 495,244 shares of company stock worth $14,079,461. 3.80% of the stock is currently owned by company insiders.

Maplight Therapeutics Stock Down 2.9%

MPLT opened at $27.16 on Wednesday. The business has a 50 day moving average price of $28.56 and a two-hundred day moving average price of $21.73. The company has a market cap of $1.16 billion and a PE ratio of -0.66. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, sell-side analysts expect that Maplight Therapeutics, Inc. will post -5.04 EPS for the current fiscal year.

Maplight Therapeutics Profile

(Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.